Jan 5 (Reuters) - Metagenomi Technologies, a genetic medicines company backed by Bayer Healthcare and Moderna , filed for an initial public offering in the United States on Friday. (Reporting by Niket Nishant in Bengaluru; Editing by Pooja Desai)
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
122.7 USD | +0.66% | -2.31% | +23.37% |
09/05 | Deutsche Bank Raises Moderna's Price Target to $85 From $70 | MT |
07/05 | UBS Adjusts Moderna Price Target to $151 From $143, Maintains Buy Rating | MT |
Stocks mentioned in the article
Price
|
Change
|
5d. change
|
Capi.
| ||
---|---|---|---|---|---|
122.7 USD | +0.66% | -2.31% | 46.71B | ||
28.69 EUR | +0.76% | +4.90% | 30.06B | ||
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+23.37% | 46.71B | |
+48.83% | 41.8B | |
-0.94% | 41.52B | |
-5.86% | 29.55B | |
+11.29% | 25.78B | |
-20.92% | 19.26B | |
+3.20% | 12.14B | |
-2.67% | 12.08B | |
+30.23% | 11.98B | |
+20.99% | 11.58B |
- Stock Market
- Equities
- MRNA Stock
- News Moderna, Inc.
- Moderna-backed genetic drugs firm Metagenomi files for US IPO